Works matching DE "CRIZOTINIB"

Results: 400

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

Published in:

NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00663-1

By:

Thawani, Rajat;
Repetto, Matteo;
Keddy, Clare;
Nicholson, Katelyn;
Jones, Kristen;
Nusser, Kevin;
Beach, Catherine Z.;
Harada, Guilherme;
Drilon, Alexander;
Davare, Monika A.

Publication type:

Article

Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer.

Published in:

NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-023-00489-3

By:

Tan, Yan Qin;
Chiou, Yi-Shiou;
Guo, Hui;
Zhang, Shuwei;
Huang, Xiaoming;
Dukanya, Dukanya;
Kumar, Arun M.;
Basappa, Shreeja;
Liu, Suling;
Zhu, Tao;
Basappa, Basappa;
Pandey, Vijay;
Lobie, Peter E.

Publication type:

Article

Co-delivery of F7 and crizotinib by thermosensitive liposome for breast cancer treatment.

Published in:

Journal of Liposome Research, 2022, v. 32, n. 3, p. 265, doi. 10.1080/08982104.2021.2001499

By:

Li, Mingyuan;
Li, Yuan;
Li, Shiqin;
Jia, Lin;
Du, Chunyang;
Li, Meng;
Li, Shuangshuang;
Galons, Hervé;
Guo, Na;
Yu, Peng

Publication type:

Article

Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study.

Published in:

Journal of Clinical Medicine, 2018, v. 7, n. 6, p. 129, doi. 10.3390/jcm7060129

By:

Reynolds, Craig;
Masters, Elizabeth T.;
Black-Shinn, Jenny;
Boyd, Marley;
Mardekian, Jack;
Espirito, Janet L.;
Chioda, Marc

Publication type:

Article

Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study.

Published in:

Oncology Letters, 2024, v. 27, n. 5, p. N.PAG, doi. 10.3892/ol.2024.14357

By:

Liu, Qing;
Fu, Ying;
Guo, Jun;
Fu, Chunqiu;
Tang, Ning;
Zhang, Chufeng;
Han, Xiao;
Wang, Zhehai

Publication type:

Article

Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A‑ROS1 rearrangement: A case report.

Published in:

2023

By:

Kinoshita, Ryosuke;
Nakao, Makoto;
Kiyotoshi, Hiroko;
Hayashi, Syuntaro;
Sugihara, Masahiro;
Hirata, Yuya;
Kuriyama, Mamiko;
Takeda, Norihisa;
Muramatsu, Hideki

Publication type:

Case Study

Crizotinib changes the metabolic pattern and inhibits ATP production in A549 non-small cell lung cancer cells.

Published in:

Oncology Letters, 2021, v. 21, n. 1, p. N.PAG

By:

Ye, Sa;
Zhou, Hong-Bin;
Chen, Ying;
Li, Kai-Qiang;
Jiang, Shan-Shan;
Hao, Ke

Publication type:

Article

Crizotinib induces apoptosis of lung cancer cells through JAK-STAT pathway.

Published in:

Oncology Letters, 2018, v. 16, n. 5, p. 5992, doi. 10.3892/ol.2018.9387

By:

Lu, Hongmin;
Wu, Shibo;
Chen, Huafei;
Huang, Ying;
Qiu, Guoqin;
Liu, Lingxiang;
Li, Yong

Publication type:

Article

A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer.

Published in:

Oncology Letters, 2018, v. 15, n. 6, p. 8703, doi. 10.3892/ol.2018.8444

By:

Jin, Ying;
ChEN, Yamei;
Yu, Xinmin;
Shi, Xun

Publication type:

Article

Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report.

Published in:

Oncology Letters, 2017, v. 14, n. 6, p. 7545, doi. 10.3892/ol.2017.7167

By:

Stanek, Libor;
Springer, Drahomira;
Konopasek, Bohuslav;
Vocka, Michal;
Tesarova, Petra;
Syrucek, Martin;
Petruzelka, Lubos;
Vicha, Ales;
Musil, Zdenek

Publication type:

Article

Assessment of ALK gene fusions in lung cancer using the differential expression and exon integrity methods.

Published in:

Oncology Letters, 2016, v. 11, n. 3, p. 1651, doi. 10.3892/ol.2016.4157

By:

QING HUANG;
QIUHUA DENG;
LEI JIANG;
RONG FANG;
YINGHUA QIU;
PING WANG;
ZHOU, JEFF X.;
HAIHONG YANG

Publication type:

Article

Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer (Review).

Published in:

Oncology Letters, 2016, v. 11, n. 1, p. 3, doi. 10.3892/ol.2015.3901

By:

ANTONELLI, GIOVANNA;
LIBRA, MASSIMO;
PANEBIANCO, VINCENZO;
RUSSO, ALESSIA ERIKA;
VITO VITALE, FELICE;
COLINA, PAOLO;
D'ANGELO, ALESSANDRO;
ROSSELLO, ROSALBA;
FERRAÙ, FRANCESCO

Publication type:

Article

Primary signet-ring cell carcinoma of the lung treated with crizotinib: A case report.

Published in:

2015

By:

YUE-QIN HAO;
HUA-PING TANG;
HONG-YUN LIU

Publication type:

Case Study

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report.

Published in:

Oncology Letters, 2015, v. 9, n. 4, p. 1537, doi. 10.3892/ol.2015.2897

By:

ALÌ, GRETA;
CHELLA, ANTONIO;
LUPI, CRISTIANA;
PROIETTI, AGNESE;
NICCOLI, CRISTINA;
BOLDRINI, LAURA;
DAVINI, FEDERICO;
MUSSI, ALFREDO;
FONTANINI, GABRIELLA

Publication type:

Article

Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient.

Published in:

2018

By:

Yang, Shaoyu;
Wu, Liming;
Li, Xin;
Huang, Jie;
Zhong, Jianbo;
Chen, Xueqin

Publication type:

Case Study

Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Published in:

2017

By:

YUTO YASUDA;
YASUYO NISHIKAWA;
YUICHI SAKAMORI;
MAKOTO TERAO;
KENTARO HASHIMOTO;
TOMOKO FUNAZO;
TAKASHI NOMIZO;
TAKAHIRO TSUJI;
HIRONORI YOSHIDA;
HIROKI NAGAI;
HIROAKI OZASA;
TOYOHIRO HIRAI;
YOUNG HAK KIM

Publication type:

Case Study

Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report.

Published in:

Molecular & Clinical Oncology, 2015, v. 3, n. 4, p. 149, doi. 10.3892/mco.2015.531

By:

HIROKO WATANABE;
TOMOHIRO TAMURA;
TOSHIHIRO SHIOZAWA;
GEN OHARA;
KATSUNORI KAGOHASHI;
MIO KAWAGUCHI;
KOICHI KURISHIMA;
HIROAKI SATOH;
NOBUYUKI HIZAWA

Publication type:

Article

Acid‐Catalyzed Rearrangements of 3‐Aryloxirane‐2‐Carboxamides: Novel DFT Mechanistic Insights.

Published in:

ChemistryOpen, 2020, v. 9, n. 7, p. 743, doi. 10.1002/open.202000110

By:

Qu, Zheng‐Wang;
Zhu, Hui;
Katsyuba, Sergey A.;
Mamedova, Vera L.;
Mamedov, Vakhid A.;
Grimme, Stefan

Publication type:

Article

Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway.

Published in:

Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.620934

By:

Guo, Lin;
Gong, Hui;
Tang, Ting-Li;
Zhang, Bi-Kui;
Zhang, Lei-Yi;
Yan, Miao

Publication type:

Article

A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report.

Published in:

2024

By:

Zhou, Danfei;
Ying, Jun;
Hu, Shanshan;
Li, Jiangdong;
Liu, Haijian

Publication type:

Case Study

Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion.

Published in:

2023

By:

He, Jing;
Yao, Youyuan;
Quan, Fei;
Lu, Zhongyu;
Wang, Jian;
Gao, Wen

Publication type:

Case Study

Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report.

Published in:

2023

By:

Shi, Junmei;
Jia, Zhaohui;
Zhou, Zhiguo;
Zhao, Liyan;
Meng, Qingju;
Liu, Yibing

Publication type:

Case Study

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report.

Published in:

2023

By:

Zhang, Xiangming;
Ni, Kai;
Chen, Huijun

Publication type:

Case Study

Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report.

Published in:

OncoTargets & Therapy, 2022, v. 15, p. 831, doi. 10.2147/OTT.S372134

By:

Lin, YunYu;
Lei, Yan;
Li, LinWei;
Su, Xiaoxing;
Tian, Qiqi;
Wu, Wendy

Publication type:

Article

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 5471, doi. 10.2147/OTT.S340984

By:

Shen, Gang;
Du, Yinping;
Shen, Jifang;
Zhang, Junling;
Xia, Xihua;
Huang, Mengli;
Shen, Wenxiang

Publication type:

Article

Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 3949, doi. 10.2147/OTT.S312889

By:

Leyrat, Brice;
Durando, Xavier;
Veyssiere, Hugo;
Bernadach, Maureen

Publication type:

Article

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 3037, doi. 10.2147/OTT.S291801

By:

Piha-Paul, Sarina A;
Dumbrava, Ecaterina E;
Nair, Binoj C;
Xiong, Wendy;
Xu, Li;
Mostorino, Rosa;
Subbiah, Vivek;
Tannir, Nizar;
Fu, Siqing;
Naing, Aung;
Janku, Filip;
Karp, Daniel D;
Patel, Shreyaskumar;
Daw, Najat C;
Hong, David;
Meric-Bernstam, Funda;
Zinner, Ralph

Publication type:

Article

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 11499, doi. 10.2147/OTT.S278907

By:

Lan, Shaowei;
Li, Hui;
Liu, Ying;
Xu, Jinhua;
Huang, Zhicheng;
Yan, Shi;
Zhang, Qiang;
Cheng, Ying

Publication type:

Article

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 10387, doi. 10.2147/OTT.S270961

By:

Shu, Yun;
Li, Hui;
Shang, Hongjuan;
Chen, Jun;
Su, Xiaoxing;
Le, Wei;
Lei, Yan;
Tao, Liming;
Zou, Cailiang;
Wu, Wendy

Publication type:

Article

Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 8313, doi. 10.2147/OTT.S258067

By:

Cai, Chengzhi;
Long, Yaling;
Li, Yanying;
Huang, Meijuan

Publication type:

Article

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 7101, doi. 10.2147/OTT.S265974

By:

Zeng, Liang;
Li, Yizhi;
Xu, Qinqin;
Jiang, Wenjuan;
Lizaso, Analyn;
Mao, Xinru;
Zhang, Yongchang;
Yang, Nong;
Wang, Zhenxing

Publication type:

Article

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer.

Published in:

OncoTargets & Therapy, 2019, v. 12, p. 3305, doi. 10.2147/OTT.S198827

By:

Zhang, Limin;
Wang, Yan;
Zhao, Chao;
Shi, Jinpeng;
Zhao, Sha;
Liu, Xiaozhen;
Jia, Yijun;
Zhu, Tao;
Jiang, Tao;
Li, Xuefei;
Zhou, Caicun

Publication type:

Article

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 6937, doi. 10.2147/OTT.S176273

By:

Zeng, Liang;
Li, Yizhi;
Xiao, Lili;
Xiong, Yi;
Liu, Li;
Jiang, Wenjuan;
Heng, Jianfu;
Qu, Jingjing;
Yang, Nong;
Zhang, Yongchang

Publication type:

Article

lincROR influences the stemness and crizotinib resistance in EML–ALK<sup>+</sup> non-small-cell lung cancer cells.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 3649, doi. 10.2147/OTT.S165290

By:

Yang, Yonghua;
Huang, Jingyu;
Xie, Nianlin;
Huang, Hu;
Xu, Shaogan;
Cai, Jun;
Qi, Shuai

Publication type:

Article

PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review.

Published in:

2018

By:

Yang, Li;
Wu, Yufeng;
Tang, Hong;
Zhao, Jiuzhou;
Zhao, Dongdong;
Yang, Sen;
Wang, Qiming

Publication type:

Case Study

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 1117, doi. 10.2147/OTT.S148363

By:

Aguado, Cristina;
Gil, Maria-de-los-Llanos;
Yeste, Zaira;
Giménez-Capitán, Ana;
Teixidó, Cristina;
Karachaliou, Niki;
Viteri, Santiago;
Rosell, Rafael;
Molina-Vila, Miguel A

Publication type:

Article

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 1105, doi. 10.2147/OTT.S156170

By:

Fan, Junsheng;
Xia, Zengfei;
Zhang, Xiaoli;
Chen, Yuqing;
Qian, Ruolan;
Liu, Sihan;
You, Danming;
Zhang, Jian;
Luo, Peng

Publication type:

Article

Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.

Published in:

OncoTargets & Therapy, 2017, v. 10, p. 4869, doi. 10.2147/OTT.S148604

By:

Ayoub, Nehad M.;
Al-Shami, Kamal M.;
Alqudah, Mohammad A.;
Mhaidat, Nizar M.

Publication type:

Article

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report.

Published in:

2017

By:

You-cai Zhu;
Kai-qi Du;
Xing-hui Liao;
Wen-xian Wang;
Chun-wei Xu;
Li-hua Zhong;
Yan-ping Chen;
Gang Chen;
Wu Zhuang;
Mei-yu Fang

Publication type:

Case Study

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.

Published in:

OncoTargets & Therapy, 2016, v. 9, p. 6361, doi. 10.2147/OTT.S98347

By:

Passaro, Antonio;
Lazzari, Chiara;
Karachaliou, Niki;
Spitaleri, Gianluca;
Pochesci, Alessia;
Catania, Chiara;
Rosell, Rafael;
de Marinis, Filippo

Publication type:

Article

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report.

Published in:

OncoTargets & Therapy, 2016, v. 9, p. 6059, doi. 10.2147/OTT.S112833

By:

Jumpei Kashima;
Yusuke Okuma;
Tsunekazu Hishima

Publication type:

Article

Bilateral breast adenocarcinomas with EML4- ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?

Published in:

OncoTargets & Therapy, 2016, v. 9, p. 3589, doi. 10.2147/OTT.S104583

By:

Chao Liu;
Lijuan Ding;
Bing Sun;
Shikai Wu

Publication type:

Article

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFRtyrosine kinase inhibitor.

Published in:

OncoTargets & Therapy, 2016, v. 9, p. 211, doi. 10.2147/OTT.S97100

By:

Wenxian Wang;
Xiaowen Jiang, a;
Zhengbo Song;
Yiping Zhang

Publication type:

Article

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer.

Published in:

OncoTargets & Therapy, 2015, v. 8, p. 1321, doi. 10.2147/OTT.S83179

By:

Yusuke Okuma;
Yuichiro Tanaka;
Tina Kamei;
Yukio Hosomi;
Tatsuru Okamura

Publication type:

Article

Personalized treatment strategies for non-smallcell lung cancer in Chinese patients: the role of crizotinib.

Published in:

OncoTargets & Therapy, 2015, v. 8, p. 999, doi. 10.2147/OTT.S64664

By:

Fei-Yu Niu;
Yi-Long Wu

Publication type:

Article

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.

Published in:

OncoTargets & Therapy, 2015, v. 8, p. 885, doi. 10.2147/OTT.S67262

By:

Kanaan, Zeyad;
Kloecker, Goetz H.;
Paintal, Ajit;
Perez, Cesar A.

Publication type:

Article

Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.

Published in:

Journal of Cheminformatics, 2017, v. 9, n. 1, p. 1, doi. 10.1186/s13321-017-0229-8

By:

Narayanan, Dilip;
Gani, Osman;
Gruber, Franz;
Engh, Richard

Publication type:

Article

Synthesis of hapten, generation of specific polyclonal antibody and development of ELISA with high sensitivity for therapeutic monitoring of crizotinib.

Published in:

PLoS ONE, 2019, v. 14, n. 2, p. 1, doi. 10.1371/journal.pone.0212048

By:

Al-Shehri, Mona M.;
El-Azab, Adel S.;
El-Gendy, Manal A.;
Hamidaddin, Mohammed A.;
Darwish, Ibrahim A.

Publication type:

Article

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.

Published in:

PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0205827

By:

Lu, Shun;
Yu, Yongfeng;
Fu, Shijun;
Ren, Hongye

Publication type:

Article

Identification of Crizotinib Major Degradation Products Obtained Under Stress Conditions by RP-UHPLC-HRMS.

Published in:

Croatica Chemica Acta, 2021, v. 94, n. 1, p. 17, doi. 10.5562/cca3756

By:

Tolić, Kristina;
Runje, Mislav;
Kraljević, Tatjana Gazivoda;
Pavlović, Dragana Mutavdžić

Publication type:

Article